What does 97.9% purity on a wide-pore C18 column actually tell me about a mazdutide vial?

For reference: 97.9% · a wide-pore C18 column · mazdutide.

I want to understand what this actually establishes, as opposed to what it is being used to imply.

My concern is that I am being invited to draw a conclusion the data does not support.

What is the correct interpretation, and what is the common misreading?

It tells you 97.9 per cent of the integrated area came off a wide-pore C18 column where mazdutide comes off, and the remaining 2.1 per cent did not. That is an area statement at one wavelength, not a mass statement about the vial: 2.1 per cent of area is only 2.1 per cent of mass if every impurity absorbs exactly as strongly as the parent, which none of them do. It also says nothing about how many milligrams are in the glass — water, counter-ion and a short fill are all invisible to it. What a wide-pore C18 column does add is a constraint on what could be hiding: a column that retains by hydrophobicity separates deletion sequences well and separates isomers of identical hydrophobicity not at all.

Worth being precise here: the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

The part that matters: the chemistry of peptides at low pH and high organic-solvent concentration is not something most users have intuition for, which is why published methods exist.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

The underlying point is that detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.

Ask for the chromatogram and the system suitability data, not just the number.